Mycophenolate Mofetil Associated Molecular Profiles and DiseasesKonrad Mönks1, Andreas Bernthaler2, Irmgard Mühlberger1, Bernd Mayer1, Rainer Oberbauer2 and Paul Perco1*
- *Corresponding Author:
- Dr. Paul Perco
emergentec biodevelopment GmbH, Gersthofer Straße 29-31
1180 Vienna, Austria
Fax: +43- 1-4034966-19
E-mail: [email protected]
Received date: January 11, 2011; Accepted date: January 11, 2011; Published date: January 13, 2011
Citation: Mönks K, Bernthaler A, Mühlberger I, Mayer B, Oberbauer R, et al. (2011) Mycophenolate Mofetil Associated Molecular Profiles and Diseases. J Comput Sci Syst Biol 4:001-006. doi:10.4172/jcsb.1000068
Copyright: © 2011 Mönks K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: High-throughput Omics technologies aimed at characterizing the molecular profile of diseases together with massive scientific literature on drugs and clinical trials opened the way for matching molecular profiles and drug mode of action in the realm of drug repositioning. We developed a computational analysis workflow for linking molecular targets, drugs, and diseases, and exemplified this approach for the immunosuppressive drug mycophenolate mofetil (MMF). Methods and Results: We first established a molecular MMF footprint consisting of deregulated Omics features from two transcriptomics datasets as well as from molecular features associated with MMF based on literature search methods. This footprint, consisting of 170 unique features, was used to identify diseases of relevance to MMF in the scientific literature using Medical Subject Heading (MeSH) terms. A disease enrichment score was calculated for each disease in the MeSH hierarchy, with highly ranked diseases being potentially associated to MMF. Diseases currently mentioned in clinical trials on MMF were used to validate our approach. The area under the curve was 0.78 when using the disease enrichment scores in order to discriminate between diseases currently in clinical trials and diseases not addressed by MMF with sensitivity and specificity values of 0.38 and 0.96 respectively. Among those diseases in clinical trials showing high scores were kidney diseases, multiple sclerosis, and systemic lupus erythematosus. Conclusion: We identified a significant recovery of drug-associated diseases for the example case of MMF solely utilizing a molecular profile of the drug mode of action. The approach furthermore provided hypotheses on further diseases approachable by the given drug.